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3 (very distressed). We conducted a principal components
analysis (PCA) of baseline responses. Overall and sub-
scale scores were computed as average distress scores
across relevant symptoms. We assessed internal consis-
tency reliability using Cronbach’s alpha. We assessed
reproducibility by evaluating the intraclass correlation
coefﬁcient (ICC) between baseline and follow-up scores
among patients reporting no change in overall symptom
severity (n = 45). We compared mean GSAS scores across
subgroups of patients with varying levels of symptom
severity at baseline and varying degrees of heartburn relief
at follow-up using t-tests.
RESULTS: The mean (sd) age of the 278 patients was
43.6 (11.9) years, and most were female (65%) and 
Caucasian (77%). The PCA and reliability estimates 
suggested three subscales: gastrointestinal symptoms (GI),
regurgitation and heartburn (RHB), and upper respira-
tory manifestations (URM). The subscale and overall
scores were reliable (Cronbach’s alpha, ICC): GI = 0.81,
0.81; RHB = 0.79, 0.80; URM = 0.73, 0.72; Overall =
0.87, 0.85. Mean baseline overall and subscale scores
were at least 10% poorer among patients reporting
greater symptom severity (p < 0.01). Patients reporting
complete heartburn relief at follow-up reported 13% to
16% greater improvements in overall, GI, and RHB
scores than patients who did not experience complete
relief (p < 0.001).
CONCLUSIONS: This study conﬁrmed the reliability
and validity of the overall GSAS score. Further, re-
searchers may want to consider analyzing the GI, URM,
and RHB subscale scores as secondary indicators of
symptom distress.
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The risk of signiﬁcant injury to the gastrointestinal (GI)
tract from nonsteroidal anti-inﬂammatory drugs
(NSAIDs) has been well established. Patients concurrently
using warfarin or who have had a prior serious hospital
GI event are considered to be at high risk. In 2000, the
Veterans Affairs (VA) implemented treatment criteria for
the use of NSAIDs including cyclooxygenase–2 (COX-2)
inhibitors. The high-risk criteria-based therapy is sal-
salate, non-selective NSAID plus a proton pump inhibitor
(PPI), high-dose famotidine, or misoprostol or a COX-2
inhibitor.
OBJECTIVES: The purpose of this study was to assess
the level of criteria-based NSAID prescribing in high risk
patients at the New Mexico VA Healthcare System.
METHODS: Patients with concurrent prescriptions for
an NSAID and warfarin or previous hospital GI event
were identiﬁed utilizing VA databases. Current therapy
was compared to criteria-based therapy to assess level of
implementation.
RESULTS: Out of 7,625 NSAID users, 184 patients were
identiﬁed: concurrent warfarin (n = 98), prior hospital GI
event (n = 84), and concurrent warfarin with a previous
hospital GI event (n = 2). Fifty-eight percent were 
over the age of 65. The NSAIDs prescribed were ibu-
profen (42.4%), naproxen (20.1%), etodolac (16.8%),
indomethacin (8.2%), salsalate (5.4%), piroxicam
(3.3%), COX-2 inhibitors (2.1%), and sulindac (1.6%).
Criteria-based therapy was prescribed for 22% of
patients. Only 12% of warfarin patients and 33% of pre-
vious hospital GI event patients were prescribed criteria-
based therapy. Of the patients prescribed a non-selective
NSAID (n = 139), there were only 19% prescribed a 
criteria-based GI protective medication.
CONCLUSIONS: In this study, few patients, at high-risk
for GI complications due to NSAIDs, received criteria-
based therapy.
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The risk of signiﬁcant injury to the gastrointestinal (GI)
tract from nonsteroidal anti-inﬂammatory drugs
(NSAIDs) has been well established. The Veterans’ Affairs
(VA) implemented treatment criteria for the use of
NSAIDs including the new class of drugs, cyclooxyge-
nase–2 (COX-2) inhibitors. These criteria utilize a self-
administered Gastrointestinal Risk Assessment Tool (GI
Score), developed from the Arthritis, Rheumatism, and
Aging Medical Information System (ARAMIS) database,
to assess risk. This tool generates a composite score 
used to predict the 1-year risk level, level 1 (no risk) to
level 4 (substantial risk), for the potential of an NSAID-
associated GI event.
OBJECTIVES: The purpose of this study was to assess
the risk level and the level of implementation of the VA
criteria.
METHODS: The GI score was used to assess the patient’s
risk level calculated on the basis of data from VA demo-
graphic, prescription, hospitalization, clinic visits, and
active problem lists databases. Current therapy was 
compared to criteria-based therapy to assess level of
implementation.
RESULTS: There were 7,625 NSAID users in the New
Mexico VA Healthcare System: 86 previous hospitalized
GI event patients, 100 concurrent warfarin therapy
patients, 223 corticosteroid therapy patients, and 205
rheumatoid arthritis patients. Thirty-six percent of the 
VA patients were over the age of 65. The most commonly
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prescribed NSAIDs were ibuprofen (47%), naproxen
(22%) and etodolac (14%). The calculated risk level 
indicated that 29% of patients had substantial (4%) or
signiﬁcant (25%) risk for a potential GI event, of 
which 34% were prescribed criteria-based therapy 
(salsalate, non-selective NSAID plus proton pump
inhibitor (PPI), high-dose famotidine or misoprostol, or
COX-2 inhibitor).
CONCLUSIONS: In this study, salsalate, non-selective
NSAIDs with PPI, high-dose famotidine or misoprostol,
and COX-2 inhibitor are under utilized in patients at high
risk for a GI event.
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VISITS FOR ACUTE RESPIRATORY TRACT
INFECTIONS
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Previous investigation revealed that plan members diag-
nosed with conditions that usually have a viral etiology
receive antibiotics at high rates. Multiple reasons exist for
this inappropriate drug use. One possible reason may 
be that providers, patients, or both believe that using 
an antibiotic will prevent the onset a more serious con-
dition and thereby prevent a return visit. Identiﬁcation of
the causes of antibiotic use will help design interven-
tions to control the development of antibiotic-resistant
microorganisms.
OBJECTIVE: Determine the impact of antibiotic use on
return visits for acute respiratory tract infections.
METHODS: This study uses large database analysis
(insurance claims data). Inclusion criteria: age less than
65 and continuous enrollment in a non-HMO beneﬁt
plan with medical, hospital, and pharmaceutical cover-
age. Cases were identiﬁed as an outpatient service for a
common cold, upper respiratory tract infection, or acute
bronchitis. Antibiotic use was deﬁned as a prescription
ﬁlled within seven days of the respiratory tract infection.
Patients were followed for an additional 30 days to deter-
mine whether they had a subsequent service for a respi-
ratory tract infection or related condition.
RESULTS: There were 173,469 patients who met study
criteria, overall 101,446 received antibiotics (58.48%).
For those who received an antibiotic, 14,600 (14.39%)
returned for a respiratory tract infection within 30 days
of their initial diagnosis. Of those not receiving an 
antibiotic at their ﬁrst visit (72,023), 12.27% returned 
for a subsequent respiratory tract infection within 30 days
of their initial diagnosis. Although the difference between
the groups is statistically signiﬁcant (p < 0.0001), the
magnitude is not clinically signiﬁcant.
CONCLUSION: The use of antibiotics for acute respira-
tory tract infections does not affect the rate of return for
subsequent visits within 30 days. Communicating this
information to providers and patients could help reduce
the inappropriate use of antibiotics.
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Serious infections in neutropenic patients may have mor-
tality rates in excess 40%, even when properly treated.
OBJECTIVE: This retrospective database analysis was
performed to examine the mortality, length of stay and
cost of imipenem/cilastin versus piperacillin/tazobactam
in the treatment of seriously infected neutropenic
patients.
METHODS: The data were collected from July 1997 to
June 1998 at 90 non-government non-specialty acute care
hospitals over 100 beds throughout the United States. The
data collected at discharge included UB-92, diagnostics,
procedures, ICD-9’s, DRG and drug dispensing data. All
patients in the analysis were coded for a serious infection,
primarily pneumonia (481 to 486.99) or septicemia (038
to 038.9), and neutropenia (284,284.4, 284.9 and 288).
RESULTS: The database analysis identiﬁed 16,396 on
mipenem/cilastin or piperacillin/tazobactam over 18 years
of age. Of those treated with these agents, 2,563 were
infected neutropenia patients. The length of stay was 
not statistically signiﬁcant between the two groups. 
Difference in utilization patterns demonstrates the
imipenem/cilastin group had a statistically signiﬁcant (p
< 0.05) greater use as a third line (16%) agent and less
as a ﬁrst line agent (61%) than the piperacillin/tazobac-
tam group (10% and 68% respectively). Mortality rates
indicated imipenem/cilastin had statistically signiﬁcant
lower mortality rate (17.1%) versus the piperacillin/
tazobactam (20.6%) group in the treatment groups.
Overall cost was $1,130 lower in the imipenem/cilastin
treated group despite the fact the drug cost was $267
higher. 
CONCLUSION: In this study population, imipenem/
cilastin has a lower mortality rate, a higher drug cost and
lower overall treatment cost in infected neutropenic
patients when compared to piperacillin/tazobactam.
